Long-term neurodevelopmental outcomes after intrauterine transfusion for alloimmune hemolytic disease of the fetus and newborn

The mainstay for the management and treatment of severe alloimmune hemolytic disease of the fetus and newborn (HDFN) is based on timely detection and intrauterine transfusions (IUT) in cases with severe fetal anemia. Although long-term neurodevelopmental outcomes in children born following IUT for HDFN are nowadays considered 'favorable', reliable long-term outcome data remain scarce. Several studies suggests that children with a history of severe hydrops, cerebral injury, and preterm birth are at increased risk for neurodevelopmental impairment (NDI). However, follow-up studies are limited by small sample sizes, the absence of control groups, inconsistent criteria for neurodevelopmental outcome, and a lack of standardized developmental assessments. The prevalence of NDI in the literature to date is reported to be around 5 % but varies from 0 % to 18.8 %, depending on the studied cohort. When interpreting the data and extrapolating conclusions to the general population, consideration must be given to the fact that the majority was born moderate to late preterm, a population inherently at increased risk for adverse neurodevelopmental outcomes. Future research should incorporate more subtle impairments, as mild to moderate cognitive deficits, learning problems and socioemotional and behavioral difficulties can substantially impact long-term care needs and socioeconomic potential. A deeper understanding of the effects of fetal anemia and IUT on neurodevelopmental trajectories will enable effective screening and the implementation of timely, targeted interventions to optimize developmental outcomes for children at risk. In addition, the impact of the complicated pregnancy on the wellbeing of parents and the child-caregiver relationship is an underexposed and understudied outcome measure. With the introduction of new non-invasive therapies, international collaborative efforts are of utmost importance to reliably investigate not just survival or neonatal outcome but also long-term neurodevelopment and wellbeing of children and caregivers.